136 related articles for article (PubMed ID: 10202279)
1. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].
Zhou DH; Ma ZM; Chen Y
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):833-7. PubMed ID: 18396641
[TBL] [Abstract][Full Text] [Related]
6. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
8. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
10. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S
J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519
[TBL] [Abstract][Full Text] [Related]
11. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer.
Shinohara S; Hanagiri T; Taira A; Takenaka M; Oka S; Chikaishi Y; Uramoto H; So T; Yamada S; Tanaka F
Oncology; 2016; 90(6):327-38. PubMed ID: 27225749
[TBL] [Abstract][Full Text] [Related]
13. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of CD44 variants expression in colorectal cancer.
Li XD; Ji M; Wu J; Jiang JT; Wu CP
Tumori; 2013; 99(1):88-92. PubMed ID: 23549006
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
Amirghofran Z; Jalali SA; Hosseini SV; Vasei M; Sabayan B; Ghaderi A
J Gastrointest Cancer; 2008; 39(1-4):73-8. PubMed ID: 19333790
[TBL] [Abstract][Full Text] [Related]
16. The Serum Assay of Soluble CD44 Standard, CD44 Variant 5, and CD44 Variant 6 in Patients with Gastric Cancer.
Yoo CH; Noh SH
Cancer Res Treat; 2003 Feb; 35(1):3-8. PubMed ID: 26680908
[TBL] [Abstract][Full Text] [Related]
17. CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.
Zhao LH; Lin QL; Wei J; Huai YL; Wang KJ; Yan HY
Int J Clin Exp Pathol; 2015; 8(1):692-701. PubMed ID: 25755763
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer W; Bechter O; Söderberg O; Nilsson K; Terol M; Greil R; Thaler J; Herold M; Finke L; Günthert U; Montserrat E; Stauder R
Leuk Res; 2004 Oct; 28(10):1043-51. PubMed ID: 15289016
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer.
Kainz C; Tempfer C; Kohlberger P; Janisch S; Koelbl H; Gitsch G; Breitenecker G
Int J Cancer; 1996 Jun; 69(3):170-3. PubMed ID: 8682582
[TBL] [Abstract][Full Text] [Related]
20. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.
Köbel M; Weichert W; Crüwell K; Schmitt WD; Lautenschläger C; Hauptmann S
Virchows Arch; 2004 Nov; 445(5):456-64. PubMed ID: 15375658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
